{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-090405","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.233111+00:00","generated_at":"2026-05-18T17:58:21.104240+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform","bullets":["CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.","CRN10329 (SST3 agonist) reduced cystic index, kidney weight, and injury markers in ADPKD mouse model; SST3 highly expressed in cyst-lining cells.","CRN09682 (NDC) showed dose-dependent anti-tumor activity in mouse models; free MMAE persisted in tumor >240 hours, cleared from plasma by 24 hours.","Phase 1/2 BRAVESST2 trial of CRN09682 expects up to 150 participants; Phase 1 dose escalation: 3-6 patients per cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-090405","json":"https://secwatch.observer/filing/0000950170-25-090405.json","markdown":"https://secwatch.observer/filing/0000950170-25-090405.md","text":"https://secwatch.observer/filing/0000950170-25-090405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/0000950170-25-090405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/crnx-20250626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:58:21.104240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}